CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Ryan Cross

Senior Science Correspondent

The promise of a one-and-done CRISPR infusion is beginning to look more real than ever.
On Thursday, Intellia Therapeutics announced that an experimental gene editing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Moldova clears first gene editing study for HBV in humans

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Roche returns to Dyno for its AAV tech with $50M upfront

Adults 50 and up should get pneumococcal vaccine, CDC advisors say, in boost to Pfizer and Merck

Zai Lab unveils early lung cancer data as it looks to challenge Amgen's Imdelltra

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Senior Science Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study